News

Syncona, an independent subsidiary of the Wellcome Trust, will invest £25m in a Series A financing. UCL professor of haematology Amit Nathwani developed Freeline's next-generation AAV gene therapy

Merck will provide funding and clinical supplies of pembrolizumab for the investigator-initiated study, which is anticipated to start in the first quarter of next year. Imprime PGG is

The acceptance of the NDA by the FDA in its 74-day letter indicates that the application permits a substantive review and there are no issues that have been

CAT-2054 is an oral small molecule that modulates the SREBP pathway. SREBP is a master regulator of lipid metabolism that impacts LDL, triglycerides and glucose with the potential

DMD is a rare form of muscular dystrophy that leads to progressive and debilitating weakening of muscles in young males. It occurs due to mutations in the gene

ALLN-177 is designed to treat secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones. Partner Fund Management led the Series C financing round, which included

The first study, Javelin Gastric 100, will compare the switch from first-line chemotherapy to maintenance therapy with avelumab versus continuation of chemotherapy. It will evaluate the potential superiority

The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) has approved Dengvaxia, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue virus serotypes

STARTRK-NG (which stands for "Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation") is a multicenter, open label, dose-escalation and expansion study designed to determine